Dicerna Pharmaceuticals (NASDAQ:DRNA) Upgraded to Strong-Buy at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other brokerages have also recently issued reports on DRNA. Chardan Capital restated a buy rating and issued a $18.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday, August 13th. HC Wainwright set a $22.00 price target on Dicerna Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 26th. ValuEngine upgraded Dicerna Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday. Leerink Swann boosted their price target on Dicerna Pharmaceuticals from $22.00 to $26.00 in a research report on Friday, November 1st. Finally, Zacks Investment Research upgraded Dicerna Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Dicerna Pharmaceuticals presently has a consensus rating of Buy and a consensus price target of $22.50.

NASDAQ:DRNA traded up $0.09 during midday trading on Friday, reaching $17.69. The company had a trading volume of 824,800 shares, compared to its average volume of 465,156. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -14.74 and a beta of 2.29. Dicerna Pharmaceuticals has a 12-month low of $9.31 and a 12-month high of $18.39. The stock’s fifty day simple moving average is $15.51 and its 200-day simple moving average is $14.24. The company has a current ratio of 3.65, a quick ratio of 3.65 and a debt-to-equity ratio of 0.01.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.15). The company had revenue of $8.04 million during the quarter, compared to analyst estimates of $11.70 million. Dicerna Pharmaceuticals had a negative net margin of 737.93% and a negative return on equity of 50.30%. As a group, sell-side analysts expect that Dicerna Pharmaceuticals will post -1.39 EPS for the current year.

In other news, insider James B. Weissman sold 14,680 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $13.07, for a total transaction of $191,867.60. Following the sale, the insider now owns 9,800 shares of the company’s stock, valued at approximately $128,086. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO John B. Green sold 12,500 shares of the business’s stock in a transaction that occurred on Thursday, October 31st. The stock was sold at an average price of $18.00, for a total value of $225,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 42,180 shares of company stock worth $686,868 in the last quarter. 21.28% of the stock is currently owned by insiders.

Large investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Dicerna Pharmaceuticals by 52.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,363 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 1,151 shares in the last quarter. Quantamental Technologies LLC increased its holdings in shares of Dicerna Pharmaceuticals by 94.4% during the 2nd quarter. Quantamental Technologies LLC now owns 3,500 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 1,700 shares during the last quarter. Bank of Montreal Can acquired a new stake in shares of Dicerna Pharmaceuticals during the 2nd quarter worth $68,000. Athanor Capital LP acquired a new stake in shares of Dicerna Pharmaceuticals during the 2nd quarter worth $233,000. Finally, Virtus ETF Advisers LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 2nd quarter worth $285,000. 83.16% of the stock is currently owned by institutional investors and hedge funds.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: Understanding the different types of bonds

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bank Ozk  Expected to Post Earnings of $0.78 Per Share
Bank Ozk Expected to Post Earnings of $0.78 Per Share
Short Interest in Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR  Grows By 6.7%
Short Interest in Telekomnks Indn Prsr Tbk Prshn Prsrn-ADR Grows By 6.7%
Titan International Inc  Short Interest Up 6.4% in October
Titan International Inc Short Interest Up 6.4% in October
Fortune Brands Home & Security  Price Target Raised to $67.00 at Royal Bank of Canada
Fortune Brands Home & Security Price Target Raised to $67.00 at Royal Bank of Canada
Hookipa Pharma’s  “Buy” Rating Reiterated at HC Wainwright
Hookipa Pharma’s “Buy” Rating Reiterated at HC Wainwright
Liberty Braves Group Series A’s  Hold Rating Reaffirmed at Evercore ISI
Liberty Braves Group Series A’s Hold Rating Reaffirmed at Evercore ISI


© 2006-2019 Ticker Report